EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of Different Sites of Microbiota Shows Increased Pseudomonas Species in the Gut Mucosa in Inflammatory Bowel Disease

David Schult-Hannemann iD, Christina Gassner, Niklas Thur, Chiara Hennig, Lisa Fricke, Lucia Liotta, Simon Weidlich, Monica Steffi Matchado, Bärbel Stecher, Leona Arps, Katja Steiger, Julius Shakhtour und 11 weitere

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izaf185 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von David Schult-Hannemann und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Clinical Department for Internal Medicine II, Technical University Munich (TUM) School of Medicine and Health, Unive…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Intestinal Mucosa, Pseudomonas, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, DFG, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is associated with changes in the gut microbiome. Studies comparing fecal, gut mucosal, and salivary microbiomes are rare, and questions remain regarding the interaction of these compartments.

Methods

In this case-control study, 16S rRNA gene amplicon sequencing was performed on samples from stool, intestinal mucosa, and saliva of 120 patients with IBD. Patients with signs of non-IBD colonic inflammation (N = 28) and healthy subjects (N = 67) served as controls. A total of 480 16S profiles were analyzed. The results were evaluated with multiple clinical and pathological parameters and potential confounders were considered. The study aimed to find microbial biomarkers specific to IBD and signatures of intestinal barrier dysfunction.

Results

Fecal α-diversity of IBD patients was reduced and Pseudomonas species was significantly increased in the mucosa of IBD patients (Pseudomonas-positive mucosa [PSM positive], P value < .001, Mann-Whitney U test). Comparison of matched stool and mucosa samples showed high abundance of Pseudomonas species in gut mucosa but not in fecal samples, especially in CD patients. Interestingly, in PSM positive, Paracoccus species, Bacteroides species, and Streptococcus species were more abundant. Importantly, the results were independent of disease severity, histopathology, medication, and other metadata.

Conclusions

The opportunistic pathogenic bacterium Pseudomonas species is more prevalent in the gut mucosa of patients with IBD. This indicates a disruption of the gut barrier with increasing mucosal colonization or invasion of the bacteria. The finding is independent of clinical metadata and confounders and occurs in new-onset IBD but not in non-IBD intestinal inflammation, which suggests disease specificity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeIntestinal MucosaPseudomonasInflammatory Bowel DiseasesSalivaColitis, UlcerativeCrohn DiseaseHumansMaleCase-Control StudiesFemaleAdultFecesMiddle AgedRNA, Ribosomal, 16SYoung Adult

Stichwörter der Autor:innen

Pseudomonasgut barrierinflammatory bowel diseasemicrobiome

Substanzen

RNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Clinical Medicine, Clinical Department for Internal Medicine II, Technical University Munich (TUM) School of Medicine and Health, University Medical Center, Technical University Munich, Munich, Germany.
  • Max-von-Pettenkofer Institute, Ludwig Maximilian University Munich, Munich, Germany.
  • Chair of Intestinal Microbiome, School of Life Sciences, Technical University Munich, Freising, Germany.
  • German Centre for Infection Research (DZIF), Partner Site Munich, Germany.
  • Institute of Pathology, Technical University Munich, Munich, Germany.
  • Institute of Pathology, University Hospital Marburg, Marburg, Germany.

ORCID-Profile: David Schult-Hannemann, Dirk Haller

Förderung

  • Deutsche Forschungsgemeinschaft
  • DFG
  • German Research Foundation
  • Microbiome Signatures

Zitieren

APA

Schult-Hannemann, D., Gassner, C., Thur, N., Hennig, C., Fricke, L., Liotta, L., Weidlich, S., Matchado, M. S., Stecher, B., Arps, L., Steiger, K., Shakhtour, J., Jesinghaus, M., List, M., Janssen, K. P., Pourjam, M., Neuhaus, K., Haller, D., Schmid, R. M., …, & ColoBAC Study Group (Collaborating Group) (2026). Comparison of Different Sites of Microbiota Shows Increased Pseudomonas Species in the Gut Mucosa in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf185

Vancouver

Schult-Hannemann D, Gassner C, Thur N, Hennig C, Fricke L, Liotta L, et al. Comparison of Different Sites of Microbiota Shows Increased Pseudomonas Species in the Gut Mucosa in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf185

BibTeX
@article{SchultHannemann2026,
  author = {Schult-Hannemann, David and Gassner, Christina and Thur, Niklas and Hennig, Chiara and Fricke, Lisa and Liotta, Lucia and Weidlich, Simon and Matchado, Monica Steffi and Stecher, Bärbel and Arps, Leona and Steiger, Katja and Shakhtour, Julius and Jesinghaus, Moritz and List, Markus and Janssen, Klaus-Peter and Pourjam, Mohsen and Neuhaus, Klaus and Haller, Dirk and Schmid, Roland M and Quante, Michael and Middelhoff, Moritz and Maurer, H Carlo and ColoBAC Study Group (Collaborating Group), ColoBAC Study Group (Collaborating Group)},
  title = {Comparison of Different Sites of Microbiota Shows Increased Pseudomonas Species in the Gut Mucosa in Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izaf185}
}
Kostenlos starten →